Cetuximab as last-line treatment for rmHNSCC outside clinical trials. A retrospective DAHANCA study

Autor: Eriksen, J. G., Nielsen, Sofie Lunden, Andersen, K. Bjerg, Mohamed, A. Qasim Ali, Nowicka-Matus, Kinga

Publikováno v: Eriksen, J G, Nielsen, S L, Andersen, K B, Mohamed, A Q A & Nowicka-Matus, K 2022, ' Cetuximab as last-line treatment for rmHNSCC outside clinical trials. A retrospective DAHANCA study ', Radiotherapy & Oncology, vol. 168, no. Suppl. 1, PO-0178, pp. S112-113 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::133585849abb44e4a68e72edf57efee3
https://vbn.aau.dk/da/publications/c1ff9c9e-b6d3-4a35-8391-6a1f4589eb56